Latanoprost in the treatment of primary open-angle glaucoma
Latanoprost, an analogue of class F2α prostaglandins, has been on the glaucoma hypotensive treatment market for almost 30 years, being the drug of first choice due to its high efficiency, good tolerability and minimal dosage. The drug is effective in all ages and is approved in pediatric practice fr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2024-12-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/1637 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394114577039360 |
|---|---|
| author | S. Yu. Petrov O. I. Markelova |
| author_facet | S. Yu. Petrov O. I. Markelova |
| author_sort | S. Yu. Petrov |
| collection | DOAJ |
| description | Latanoprost, an analogue of class F2α prostaglandins, has been on the glaucoma hypotensive treatment market for almost 30 years, being the drug of first choice due to its high efficiency, good tolerability and minimal dosage. The drug is effective in all ages and is approved in pediatric practice from 1 year. According to numerous studies, latanoprost monotherapy can reduce IOP by an average of 22–39 % from the initial level over several years; a decrease in the hypotensive effect over time has not been noted. Latanoprost is compatible with all other groups of antiglaucoma drugs, demonstrating an additive effect. |
| format | Article |
| id | doaj-art-ca0f8f582cb54554980e1f7e0963d010 |
| institution | Kabale University |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj-art-ca0f8f582cb54554980e1f7e0963d0102025-08-20T03:40:10ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602024-12-0117414114710.21516/2072-0076-2024-17-4-141-147751Latanoprost in the treatment of primary open-angle glaucomaS. Yu. Petrov0O. I. Markelova1Helmholtz National Medical Research Center of Eye DiseasesHelmholtz National Medical Research Center of Eye DiseasesLatanoprost, an analogue of class F2α prostaglandins, has been on the glaucoma hypotensive treatment market for almost 30 years, being the drug of first choice due to its high efficiency, good tolerability and minimal dosage. The drug is effective in all ages and is approved in pediatric practice from 1 year. According to numerous studies, latanoprost monotherapy can reduce IOP by an average of 22–39 % from the initial level over several years; a decrease in the hypotensive effect over time has not been noted. Latanoprost is compatible with all other groups of antiglaucoma drugs, demonstrating an additive effect.https://roj.igb.ru/jour/article/view/1637glaucomalatanoprosthypotensive treatmentmonotherapy |
| spellingShingle | S. Yu. Petrov O. I. Markelova Latanoprost in the treatment of primary open-angle glaucoma Российский офтальмологический журнал glaucoma latanoprost hypotensive treatment monotherapy |
| title | Latanoprost in the treatment of primary open-angle glaucoma |
| title_full | Latanoprost in the treatment of primary open-angle glaucoma |
| title_fullStr | Latanoprost in the treatment of primary open-angle glaucoma |
| title_full_unstemmed | Latanoprost in the treatment of primary open-angle glaucoma |
| title_short | Latanoprost in the treatment of primary open-angle glaucoma |
| title_sort | latanoprost in the treatment of primary open angle glaucoma |
| topic | glaucoma latanoprost hypotensive treatment monotherapy |
| url | https://roj.igb.ru/jour/article/view/1637 |
| work_keys_str_mv | AT syupetrov latanoprostinthetreatmentofprimaryopenangleglaucoma AT oimarkelova latanoprostinthetreatmentofprimaryopenangleglaucoma |